Clinical Trial Update: A Study With RO4917523 in Patients With Fragile X Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 study of RO4917523 in Fragile X Syndrome has completed, sponsored by Hoffmann-La Roche.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• RO4917523

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Fragile X Syndrome | Phase 2 | Status: COMPLETED